2.12 USD
▼-0.02-0.47%
盘后 2.06 -3.12%
2026-08-03
市值
$5.83M
市盈率
—
EPS
-7.54
股息率
—
52 周区间
1.67 – 14.24
成交量
151.86K
Beta
0.99
目标价
—
52W 低 1.6752W 高 14.24
价格走势
公司简介
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta...